Evidence map›Paper›PMID 33450276›Full record

ArticleNeuropharmacology2021

Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.

Gwenn S Smith, Hiroto Kuwabara, Neda F Gould, Najilla Nassery, Alena Savonenko, Jin Hui Joo, Kristin L Bigos, Michael Kraut, James Brasic, Daniel P Holt and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review of Emotion Regulation in Late Life Mood Disorders.Journal of psychiatry and brain science · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Gwenn S SmithDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: gsmith95@jhmi.edu.
Hiroto KuwabaraDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Neda F GouldDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Najilla NasseryDivision of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alena SavonenkoDepartment of Pathology (Neuropathology), Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jin Hui JooDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kristin L BigosDepartment of Medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael KrautDivision of Neuroradiology, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
James BrasicDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel P HoltDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew W HallDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William B MathewsDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert F DannalsDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ayon NandiDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Clifford I WorkmanDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Longitudinal Molecular Imaging of Neuropathology and Serotonin in Mild Cognitive ImpairmentR01AG059390 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2018 to 2022
$4.8M
Geriatric Depression: PET Studies of Pathophysiology and Treatment ResponseR01MH086881 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2010 to 2013
$2.7M
Longitudinal imaging of neuropsychiatric symptoms in mild cognitive impairmentR01AG041633 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2011 to 2015
$2.6M
PET Studies of Serotonin and Amyloid in MCIR01AG038893 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2011 to 2014
$2.4M
Serotonin Modulation in Geriatric DepressionR01MH064823 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S. · 2003 to 2006
$1.9M
NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR003098NIA NIH HHS R01 AG038893NIA NIH HHS R01 AG041633NIA NIH HHS R01 AG059390NIMH NIH HHS R01 MH064823NIMH NIH HHS R01 MH086881
6 · The paper itself

Abstract

Patients with late-life depression (LLD) have a more variable response to pharmacotherapy relative to patients with mid-life depression. Degeneration of the serotonergic system and lower occupancy of the initial target for antidepressant medications, the serotonin transporter (5-HTT), may contribute to variability in treatment response. The focus of this study was to test the hypotheses that lower cortical and limbic serotonin transporter (5-HTT) availability in LLD patients relative to controls and less 5-HTT occupancy by antidepressant medications would be associated with less improvement in mood and cognition with treatment in LLD patients. Twenty LLD patients meeting DSM-IV criteria for a current major depressive episode and 20 non-depressed controls underwent clinical and neuropsychological assessments, magnetic resonance imaging to measure gray matter volumes and high-resolution positron emission tomography (PET) scanning to measure 5-HTT before and after 10-12 weeks of treatment with Citalopram or Sertraline (patients only). Prior to treatment, 5-HTT was lower in LLD patients relative to controls in mainly temporal cortical and limbic (amygdala and hippocampus) regions. Gray matter volumes were not significantly different between groups. 5-HTT occupancy was detected throughout cortical, striatal, thalamic and limbic regions. The magnitude of regional 5-HTT occupancy by antidepressants was 70% or greater across cortical and sub-cortical regions, consistent with the magnitude of 5-HTT occupancy observed in mid-life depressed patients. Greater regional 5-HTT occupancy correlated with greater improvement in depressive symptoms and visual-spatial memory performance. These data support the hypothesis that serotonin degeneration and variability in 5-HTT occupancy may contribute to heterogeneity in treatment response in LLD patients.

Indexed as

AffectAgedAged, 80 and overAgingAntidepressive AgentsBrainCitalopramFemaleHumansMagnetic Resonance ImagingMajor Depressive DisorderMaleMiddle AgedMolecular ImagingSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsAntidepressive AgentsCitalopramSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsSertralineAgingCitalopramLate-life depressionPositron emission tomography (PET)Selective serotonin reuptake inhibitorsSerotonin transporterSertraline

Identifiers

PMID33450276
PMCPMC8716112
OpenAlexW3120524518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.